



Akasaka Intercity, 1-11-44, Akasaka, Minato-ku, Tokyo 107-0052
Phone +81-3-6299-8905 Fax +81-3-6299-8922
<http://corporate.m3.com> pr@m3.com

Seeds Rocket Business Launch

~ Initial Seed: MedTecHeart's Next Generation Artificial Heart Development ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura, URL: <http://corporate.m3.com/>, "M3" below) announced the launch of a new "seeds rocket" business to boost promising start-ups or technologies by holding a stake in and providing comprehensive support towards the development of that business. The first investment has been made through M3i, Inc. (Headquarters: Tokyo, Japan; CEO: Kazuhiro Umeda, "M3i" below), a newly established seed investment company, into a next generation artificial heart being developed by MedTecHeart, Inc. (Headquarters: Tokyo, Japan; CEO: Setsuo Takatani, URL: <http://www.medtechheart.com>, "MedTecHeart" below).

M3 operates m3.com, a 250,000 physician member web portal designed for healthcare professionals in Japan, and provides marketing support for pharmaceutical companies centered around "MR-kun family" services which offers drug related information to doctors via the internet, as well as clinical trial related services centered around "Mr. Finder" which excavates institutions and patient participants for clinical studies. Furthermore, we have consolidated Integrated Development Associates Co., Ltd. ("IDA" below) and POC Clinical Research Inc. ("POC" below) over the past year to provide strategy consulting and support services for the development of new drugs and healthcare devices.

This newly launched seeds rocket business will not only be limited to actualizing an idea and an initial capital investment, but also includes provision of comprehensive support across the entire value chain of launching and developing a new business, such as allocating management resources, advising development strategies for new drugs or devices, clinical trial implementation, and marketing support, all to expedite the growth process to unprecedented rocket speeds. The newly established seeds investment company, M3i, will be central in directing the sourcing as well as investment in and enterprise value development of the seeds. As its initial deal, M3i has invested in MedTecHeart, which is developing a next generation artificial heart. M3i plans to increase the number of investments seeds going forward.

■ Seeds Rocket Business



■ M3i, Inc.

Established: January 2016
 Address: Tokyo, Japan
 Business Description: Seeds rocket business
 CEO: Kazuhiro Umeda

■ MedTecHeart Overview

MedTecHeart is a research and development joint venture between Tokyo Medical and Dental University and Tokyo Institute of Technology, developing an extracorporeal ventricular assist device (VAD). The VAD in development has a magnetically levitated centrifugal structure offering superior safety even upon extended usage and at a lower cost, and draws a line against the currently available pulsatile pace makers and centrifugal blood pumps. Practical realization of this device will contribute to saving the lives of and improving treatment as well as the quality of life for patients with severe cardiac dysfunction.


Address: Tokyo, Japan
 CEO: Setsuo Takatani
 URL: <http://www.medtechheart.com>

Product Images:

Pump Unit



Motor Unit



Console Unit

